SPRY Stock Overview
A biopharmaceutical company, develops treatments for severe allergic reactions.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
ARS Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$9.57 |
| 52 Week High | US$11.90 |
| 52 Week Low | US$2.55 |
| Beta | 0 |
| 11 Month Change | 0.90% |
| 3 Month Change | 8.69% |
| 1 Year Change | 38.82% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 57.84% |
Recent News & Updates
Recent updates
ARS Pharmaceuticals On Track With Neffy Despite Regulatory Hurdles
Jun 25We're Not Very Worried About ARS Pharmaceuticals' (NASDAQ:SPRY) Cash Burn Rate
Mar 18
ARS Pharmaceuticals (NASDAQ:SPRY) Is In A Good Position To Deliver On Growth Plans
Nov 14Here's Why We're Not Too Worried About ARS Pharmaceuticals' (NASDAQ:SPRY) Cash Burn Situation
May 12Shareholder Returns
| SPRY | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -12.0% | -4.9% | -5.7% |
| 1Y | 38.8% | 11.5% | 14.1% |
Return vs Industry: SPRY exceeded the US Biotechs industry which returned 13.1% over the past year.
Return vs Market: SPRY exceeded the US Market which returned 14.1% over the past year.
Price Volatility
| SPRY volatility | |
|---|---|
| SPRY Average Weekly Movement | 7.6% |
| Biotechs Industry Average Movement | 10.5% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 14.6% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: SPRY has not had significant price volatility in the past 3 months.
Volatility Over Time: SPRY's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 25 | Rich Lowenthal | ars-pharma.com |
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.
ARS Pharmaceuticals, Inc. Fundamentals Summary
| SPRY fundamental statistics | |
|---|---|
| Market cap | US$948.09m |
| Earnings (TTM) | -US$44.84m |
| Revenue (TTM) | US$500.00k |
1,854x
P/S Ratio-20.7x
P/E RatioIs SPRY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SPRY income statement (TTM) | |
|---|---|
| Revenue | US$500.00k |
| Cost of Revenue | US$20.07m |
| Gross Profit | -US$19.57m |
| Other Expenses | US$25.28m |
| Earnings | -US$44.84m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.46 |
| Gross Margin | -3,913.20% |
| Net Profit Margin | -8,968.40% |
| Debt/Equity Ratio | 0% |
How did SPRY perform over the long term?
See historical performance and comparison